Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

By M. Slovak, K. Kopecky, P. Cassileth, D. H. Harrington, K. Theil, A. Mohamed, E. Paietta, C. Willman, D. Head, J. Rowe and 2 more. 2000

802 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/391d79234259c67a1b6a75cc170b76bf0bc9f274

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. D. Gilliland

Citations in the corpus

• Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. (2008, background): “In direct comparisons, MK provides significantly better prognostic prediction than the traditionally defined complex karyotype, which considers any three or more or five or more clonal cytogenetic abnormalities, and also than various individual specific cytogenetic abnormalities (eg, del[5q], inv[3]”
• Drug therapy for acute myeloid leukemia. (2005, background): “For example, RUNX1-ETO and CBF -MYH11 associated with t(8;21) and inv(16), respectively, aberrantly recruit the nuclear corepressor complex to RUNX1 target genes.”